Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips' subsidiary, Philips Respironics, has issued a voluntary alert regarding certain CPAP and Bi-Level PAP masks with magnetic headgear clips. These masks should not be used by or near individuals with implanted metallic medical devices due to potential magnetic interference. The company has distributed over 17 million such masks and received 14 reports of adverse effects linked to the magnets, including pacemaker failure and seizures. Users are advised to discontinue use and consult a physician for alternatives.
On September 6, 2022, Royal Philips (NYSE: PHG) announced the successful treatment of patients using its innovative VeriSight Pro, a real-time 3D intracardiac echocardiography catheter, at Baptist Health's Miami Cardiac & Vascular Institute. This technology enhances procedural efficiency by reducing the need for sedation, thus improving patient preparation and recovery times. The catheter features superior imaging capabilities and enables interventionalists to navigate cardiac procedures more effectively, ultimately broadening treatment options for patients with structural heart disease.
Philips (NYSE: PHG) showcased its advanced cardiology solutions at the ESC Congress in Barcelona (August 26-29, 2022). The company aims to enhance diagnostic confidence and operational efficiency, addressing rising patient demands. The Future Health Index 2022 highlights technology improvements as vital for patient management. Key innovations include integrated systems for diagnostic imaging and minimally invasive therapies, designed to optimize cardiac care workflows. Philips emphasizes data-driven insights and remote monitoring solutions to improve patient outcomes while reducing costs.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG) has announced an Extraordinary General Meeting (EGM) on September 30, 2022, to appoint Roy Jakobs as the new President and CEO, effective October 15, 2022. This meeting aims to solidify Jakobs' leadership following the departure of Frans van Houten. Key details about the EGM agenda are available online. Philips is recognized for its health technology focus, emphasizing integrated solutions across the health continuum, with 2021 sales of EUR 17.2 billion and a workforce of approximately 79,000 employees globally.
Royal Philips (NYSE: PHG) announced Roy Jakobs as the proposed successor to CEO Frans van Houten, effective October 15, 2022. The Supervisory Board made this unanimous decision after evaluating multiple candidates, highlighting Jakobs' extensive experience and operational success within the company. An Extraordinary General Meeting is scheduled for September 30, 2022, to confirm his appointment. Van Houten will assist in the transition until April 30, 2023. Jakobs aims to enhance Philips’ growth and quality focus, especially regarding recent challenges related to Respironics devices.
Royal Philips has announced a significant advancement in the treatment of peripheral vascular disease (PVD) with the publication of the world's first global consensus on the use of intravascular ultrasound (IVUS). This guidance, appearing in the Journal of the American College of Cardiology: Cardiovascular Interventions, advocates for the routine use of IVUS in all phases of lower extremity interventions. Approximately 200 million people globally suffer from PVD, highlighting the potential impact of these recommendations on patient care and clinical practices.
Philips announced a partnership with Scott Cole, a prominent voice in Esports, to promote the Philips Norelco OneBlade grooming tool among gamers. The collaboration aims to inspire esports athletes to look and feel their best, enhancing their confidence and performance. Cole, known for his engaging commentary, emphasizes how the OneBlade simplifies grooming, preventing cuts and nicks while providing a clean look. Philips expanded the OneBlade range earlier this year, launching a product designed for new shavers. This initiative aligns with Philips' commitment to improving self-care among esports competitors.
Philips reported second-quarter sales of EUR 4.2 billion, marking a 7% decline due to supply shortages and COVID lockdowns in China. Operating income fell to EUR 11 million from EUR 85 million in Q2 2021, with adjusted EBITA at EUR 216 million (5.2% of sales). Operating cash flow was negative at EUR 306 million. Despite challenges, the order book grew 1%, although order intake in China declined significantly. The full-year outlook is revised to 1-3% sales growth and 10% EBITA margin, aiming for 4-6% sales growth and 14-15% EBITA margin by 2025.
Philips (NYSE: PHG) showcases its AI-powered imaging systems at the European Congress of Radiology, emphasizing their role in enhancing diagnostic confidence and reducing staff burnout. The company highlights innovations like SmartSpeed AI MR software, which accelerates scans by three times without quality loss, and the Spectral CT 7500, achieving a 34% reduction in diagnosis time. Philips aims to address operational inefficiencies in radiology, with a focus on workflow solutions that boost productivity and patient engagement.
Philips has announced that its SmartSpeed AI-based MR software has received FDA 510(k) clearance. This breakthrough software enhances MR imaging with 3 times faster scan times and improves image resolution by up to 65%. It supports 97% of clinical protocols, catering to a wide range of patients, including those with complex conditions. The software aims to increase efficiency in radiology departments, addressing challenges with rising caseloads and clinician burnout. This marks a significant advancement in diagnostic confidence and productivity within the healthcare sector.